ArticleFrontiers in molecular biosciences2022
Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma.
Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- A two-gene prognostic model for lung adenocarcinoma using summary-data-based Mendelian randomization analysis and Cox proportional hazards regression.Future science OA · 2026Article
- The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.Cancer immunology, immunotherapy : CII · 2026Article
- Emodin triggers cuproptosis to suppress hepatocellular carcinoma via SLC7A11/FDX1 axis.Frontiers in oncology · 2026Article
- The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecular Mechanisms to Therapeutic Opportunities.OncoTargets and therapy · 2026Review
- The Progress of Ferroptosis of Immune Cells in the Tumor Microenvironment and Its Impact on Tumorigenesis and Development.Immunity, inflammation and disease · 2026Review
- Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation.Journal of nanobiotechnology · 2025Article
- Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours.Biomolecules · 2025Review
- Research of SLC7A11 to estimate the prognosis and immune infiltration landscape for breast cancer.Discover oncology · 2025Article
- Adenosine AFEBS open bio · 2025Article
- Integrative Disulfidptosis-Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma.Journal of cellular and molecular medicine · 2025Article
- Article
- Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer.World journal of gastrointestinal oncology · 2024Review
- Up-regulated ORC1 promotes lung adenocarcinoma by inhibiting ferroptosis via SLC7A11 dependent pathway.Heliyon · 2024Article
- The E3 ligase TRIM7 suppresses the tumorigenesis of gastric cancer by targeting SLC7A11.Scientific reports · 2024Article
- Immunomodulation of cuproptosis and ferroptosis in liver cancer.Cancer cell international · 2024Review
- Glutaminolysis of CD4Journal of inflammation research · 2024Review
- Pien-Tze-Huang prevents hepatocellular carcinoma by inducing ferroptosis via inhibiting SLC7A11-GSH-GPX4 axis.Cancer cell international · 2023Article
- The current status and future of PD-L1 in liver cancer.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.